Hui Chen, MD
Hematology & Oncology · Suffolk, VANPI 1710237185
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,125 of the $5,480 with a category attached, or 75.3%. AstraZeneca accounts for 77.3% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $3,168, more than ten times the $214 reported in 2019.
Across 48 payments — averaging $114.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Lilly USA, LLC$309
- Bristol Myers Squibb$261
- Pfizer$114
- Seagen Inc.$100
- AVEO Pharmaceuticals, Inc.$99
- plus $359 from 11 others
Across 22 payments — averaging $10,069 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$222K
What the payments were for
- Consulting fees$4,12575%
- Food & beverage$92117%
- Education$4348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $4,238 |
| Lilly USA, LLC | 4 | $309 |
| Bristol Myers Squibb | 14 | $261 |
| Pfizer | 6 | $114 |
| Seagen Inc. | 1 | $100 |
| AVEO Pharmaceuticals, Inc. | 1 | $99 |
| Merck | 4 | $77 |
| Johnson & Johnson | 3 | $54 |
| Novartis | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Sobi, Inc | 1 | $27 |
| Beigene USA, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$4,125
How this compares
$5,480 in reported general payments places this provider in the 75th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 68 | $1,017,607 |
| XtandiEnzalutamide | 32 | $436,862 |
| PomalystPomalidomide | 14 | $316,538 |
| JakafiRuxolitinib Phosphate | 16 | $279,951 |
| NerlynxNeratinib Maleate | 11 | $247,041 |
| RevlimidLenalidomide | 11 | $225,338 |
| CalquenceAcalabrutinib Maleate | 13 | $200,287 |
| BrukinsaZanubrutinib | 11 | $166,563 |
| Imatinib Mesylate | 35 | $37,137 |
| EliquisApixaban | 19 | $11,036 |
| Letrozole | 64 | $1,287 |
| Exemestane | 22 | $1,161 |
| ValacyclovirValacyclovir Hcl | 36 | $938 |
| Prochlorperazine Maleate | 47 | $557 |
| Ondansetron Hcl | 43 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $261 | $225,33811 claims |
| AstraZenecaCalquence | $4,238 | $200,28713 claims |
| Beigene USA, Inc.Brukinsa | $25 | $166,56311 claims |
| PfizerEliquis | $114 | $11,03619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Suffolk
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.